Bio-Techne (TECH) to Release Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is expected to issue its Q2 2026 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $290.2040 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 9:00 AM ET.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $0.42 EPS for the quarter, hitting analysts’ consensus estimates of $0.42. The company had revenue of $286.56 million during the quarter, compared to the consensus estimate of $292.02 million. Bio-Techne had a net margin of 6.41% and a return on equity of 13.59%. The company’s quarterly revenue was down 1.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.42 EPS. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Price Performance

NASDAQ:TECH opened at $68.23 on Wednesday. Bio-Techne has a 52-week low of $46.01 and a 52-week high of $79.28. The company has a market cap of $10.63 billion, a P/E ratio of 139.25, a P/E/G ratio of 4.66 and a beta of 1.47. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.81 and a current ratio of 4.22. The stock’s 50-day simple moving average is $62.83 and its 200 day simple moving average is $58.70.

Bio-Techne Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 28th. Stockholders of record on Monday, November 17th were paid a dividend of $0.08 per share. The ex-dividend date was Monday, November 17th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.5%. Bio-Techne’s dividend payout ratio is currently 65.31%.

Hedge Funds Weigh In On Bio-Techne

Institutional investors and hedge funds have recently made changes to their positions in the company. Measured Wealth Private Client Group LLC acquired a new stake in Bio-Techne during the 3rd quarter worth approximately $32,000. iSAM Funds UK Ltd bought a new position in Bio-Techne during the 3rd quarter worth $33,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Bio-Techne by 506.3% during the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after buying an additional 562 shares in the last quarter. Employees Retirement System of Texas bought a new stake in shares of Bio-Techne in the third quarter valued at about $67,000. Finally, CIBC Private Wealth Group LLC grew its stake in shares of Bio-Techne by 50.6% in the third quarter. CIBC Private Wealth Group LLC now owns 2,118 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 712 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Wells Fargo & Company raised their target price on shares of Bio-Techne from $59.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Argus lifted their price objective on shares of Bio-Techne from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Thursday, November 20th. Weiss Ratings restated a “sell (d+)” rating on shares of Bio-Techne in a research note on Wednesday, January 21st. Zacks Research downgraded shares of Bio-Techne from a “hold” rating to a “strong sell” rating in a research note on Wednesday, December 17th. Finally, Deutsche Bank Aktiengesellschaft set a $72.00 price target on Bio-Techne and gave the stock a “buy” rating in a research report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Bio-Techne presently has an average rating of “Moderate Buy” and an average target price of $70.57.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.